| Systematic (IUPAC) name | |
|---|---|
| methyl 5-amino-4-oxo-pentanoate | |
| Clinical data | |
| AHFS/Drugs.com | Multum Consumer Information |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 33320-16-0 |
| ATC code | L01XD03 |
| PubChem | CID 16052023 |
| DrugBank | DB00992 |
| ChemSpider | 13180320 |
| ChEMBL | CHEMBL1096562 |
| Chemical data | |
| Formula | C6H11NO3 |
| Mol. mass | 145.156 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Methyl aminolevulinate (MAL) is a prodrug that is metabolised to Protoporphyrin IX (sensitizer) used in photodynamic therapy. It is marketed as Metvix.
Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser.
Metvix is developed by Photocure and Galderma has bought all rights to Metvix.[1]
Approved in New Zealand for treatment of basal cell carcinoma.[2]
It is now approved in many countries and has been used to treat non-melanoma skin cancer (including basal cell carcinoma).[3]
It has some advantages over Levulan.[4]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)